27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
- Novo Nordisk A/S (NYSE:NVO) has resubmitted a label expansion application to FDA for Ozempic (semaglutide) to introduce a new dose of 2.0 mg.
- Semaglutide is a glucagon-like peptide-1 (GLP-1) analog.
- The Type 2 diabetes injection is currently approved at 0.5-mg and 1-mg doses given once a week.
- The resubmission follows the Refusal to File letter received by the FDA in March.
- The agency was looking for additional information about a proposed new manufacturing site. The company said that the already-completed clinical trial program would be sufficient to approve the label expansion application.
- The standard review time by the FDA is ten months.
- Price Action: NVO shares are up 0.34% at $79.09 during the market session on the last check Friday.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!